Melanoma

National Cancer Institute awards grant for targeted radiotherapy development

Published in Cancer Weekly, September 9th, 2003

AlphaMed, Inc., announced that it has received a $500,000 2-year STTR phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

AlphaMed is collaborating with the University of Missouri in Columbia in this work. The therapy is based on a molecule, labeled with the therapeutic radionuclide lead-212, that is selective to metastatic melanoma cells. Lead-212 decays to bismuth-212, which in turn emits an alpha particle that destroys tumor cells on contact. While melanoma is understood to be relatively radioresistant, alpha particles, with their high-energy deposition, may be effective in metastatic melanoma,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry